

NDA 19452/S-017

Page 4


Derma-Smoothe/FS[®]
(fluocinolone acetonide topical oil)
Topical Oil, 0.01%

For Dermatologic Use Only-
Not for Ophthalmic Use-

NDC 28105-149-04

DESCRIPTION

Derma-Smoothe/FS[®] contains fluocinolone acetonide {(6 α , 11 β , 16 α)-6,9-difluoro-11,21-dihydroxy-16,17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone}, a synthetic corticosteroid for topical dermatologic use. Chemically, fluocinolone acetonide is C₂₄ H₃₀ F₂ O₆. It has the following structural formula:



Fluocinolone acetonide in Derma-Smoothe/FS[®] has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.

Each gram of Derma-Smoothe/FS[®] contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, refined peanut oil NF and fragrances.

CLINICAL PHARMACOLOGY

Like other topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A₂ inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A₂.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusion of topical corticosteroids can enhance penetration. Topical corticosteroids can be absorbed from normal intact skin. Also, inflammation and/or other disease processes in the skin can increase percutaneous absorption.

Derma-Smoothe/FS[®] is in the low to medium range of potency as compared with other topical

NDA 19452/S-017

Page 5

corticosteroids.

CLINICAL STUDIES

In a vehicle-controlled study for the treatment of psoriasis of the scalp in adults, after 21 days of treatment, 60% of patients on active treatment and 21% of patients on the drug vehicle had excellent to cleared clinical response.

Open-label safety studies on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis, and baseline body surface area involvement greater than 75% in 18 patients, and 50% to 75% in 15 patients, were treated with Derma-Smoothe/FS[®] twice daily for 4 weeks. Morning pre-stimulation cortisol level and post-Cortrosyn stimulation cortisol level were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 µg/dL; normal: cortisol > 7µg/dL) but all had normal responses to 0.25 mg of Cortrosyn stimulation (cortisol > 18 µg/dL).

A clinical study evaluated the response of peanut-sensitive and peanut-insensitive children to both Prick test and Patch test utilizing peanut oil NF, Derma-Smoothe/FS[®] and histamine/saline controls, on 13 individuals, 9 of whom were RAST-test positive for peanut allergens prior to the trial. These subjects were also treated with Derma-Smoothe/FS[®] twice daily for 2 weeks. Prick test and patch test results for all 13 patients were negative. Importantly, the bulk peanut oil NF, used in Derma-Smoothe/FS[®] is heated at 475° F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins.

INDICATION AND USAGE

Derma-Smoothe/FS[®] is a low to medium potency corticosteroid indicated:

In adult patients for the treatment of atopic dermatitis or psoriasis of the scalp.

In pediatric patients 2 years and older with moderate to severe atopic dermatitis. It may be used for up to 4 weeks.

CONTRAINDICATIONS

Derma-Smoothe/FS[®] is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

This product contains refined peanut oil NF (see PRECAUTIONS section).

PRECAUTIONS

General: Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.

Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation,

NDA 19452/S-017

Page 6

A.M. plasma cortisol, and urinary free cortisol tests.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Infrequently, signs and symptoms of glucocorticoid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS-Pediatric use)

Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a *failure to heal* rather than noting a clinical exacerbation, which may occur with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic testing.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Derma-Smoothe/FS[®] should be discontinued until the infection has been adequately controlled.

If wheal and flare type reactions (which may be limited to pruritus) or other manifestations of hypersensitivity develop, Derma-Smoothe/FS[®] should be discontinued immediately and appropriate therapy instituted. One peanut sensitive child experienced a flare of his atopic dermatitis during two weeks of twice daily treatment with Derma-Smoothe/FS[®].

Derma-Smoothe/FS[®] is formulated with 48% refined peanut oil NF. Peanut oil used in this product is routinely tested for peanut proteins using a sandwich enzyme-linked immunosorbent assay test (S-ELISA) kit, which can detect peanut proteins to as low as 2.5 parts per million (ppm).

Physicians should use caution in prescribing Derma-Smoothe/FS[®] for peanut-sensitive children.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. In case of contact, wash eyes liberally with water.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should promptly report to their physician any worsening of their skin condition.
4. Parents of pediatric patients should be advised not to use Derma-Smoothe/FS[®] in the treatment of diaper dermatitis. Derma-Smoothe/FS[®] should not be applied to the diaper area as diapers or plastic pants may constitute occlusive dressing.
5. This medication should not be used on the face, underarm, or groin unless directed by the physician.
6. As with other corticosteroids, therapy should be discontinued when control is achieved. If no

NDA 19452/S-017

Page 7

improvement is seen within 2 weeks, contact the physician.

Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression:

ACTH stimulation test
A.M. plasma cortisol test
Urinary free cortisol test

Carcinogenesis, mutagenesis, and impairment of fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Derma-Smoothe/FS[®]. Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide, the active ingredient in Derma-Smoothe/FS[®]. Some corticosteroids have been found to be genotoxic in various genotoxicity tests (i.e. the *in vitro* human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the *in vivo* mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test and the *in vitro* mouse lymphoma gene mutation assay).

Pregnancy: Teratogenic effects: Pregnancy category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

There are no adequate and well-controlled studies in pregnant women on teratogenic effects from Derma-Smoothe/FS[®]. Therefore, Derma-Smoothe/FS[®] should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Derma-Smoothe/FS[®] is administered to a nursing woman.

Pediatric Use: Derma-Smoothe/FS[®] may be used in pediatric patients 2 years and older with moderate to severe atopic dermatitis when used twice daily for no longer than four weeks. Derma-Smoothe/FS[®] should not be applied to the face or diaper area. Application to intertriginous areas should be avoided due to the increased possibility of local adverse events such as striae, atrophy, and telangiectasia, which may be irreversible. The smallest amount of drug needed to cover the affected areas should be applied. Long term safety in the pediatric population has not been established.

Because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of HPA-axis-suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. (SEE PRECAUTIONS).

NDA 19452/S-017

Page 8

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Derma-Smoothe/FS[®] is formulated with 48% refined peanut oil NF, in which peanut protein is not detectable at 2.5 ppm. Physicians should use caution in prescribing Derma-Smoothe/FS[®] for peanut sensitive individuals. (See PRECAUTIONS-Pediatric Use)

ADVERSE REACTIONS

The following local adverse reactions have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria. One peanut sensitive child experienced a flare of his atopic dermatitis during two weeks of twice daily treatment with Derma-Smoothe/FS[®].

OVERDOSAGE

Topically applied Derma-Smoothe/FS[®] can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

DOSAGE AND ADMINISTRATION

Atopic dermatitis in adults:

For the treatment of atopic dermatitis, Derma-Smoothe/FS[®] should be applied as a thin film to the affected area three times daily.

Scalp psoriasis in adults:

For the treatment of scalp psoriasis, wet or dampen hair and scalp thoroughly. Apply a thin film of Derma-Smoothe/FS[®] on the scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight or for a minimum of 4 hours before washing off. Wash hair with regular shampoo and rinse thoroughly.

Atopic dermatitis in pediatric patients 2 years and older:

Moisten skin. Apply Derma-Smoothe/FS[®] as a thin film to the affected areas twice daily for no longer than four weeks.

HOW SUPPLIED

Derma-Smoothe/FS[®] is supplied in bottles containing 4 fluid ounces (NDC # 28105-149-04).

Store between 20° -25° C (68° to 77° F) in tightly closed containers.

CAUTION: Rx only

NDA 19452/S-017
Page 9

MANUFACTURED BY:
Hill Laboratories, Inc.
Sanford, Florida 32773

DISTRIBUTED BY:
Hill Dermaceuticals, Inc.
Sanford, Florida 32773

Rev. CODE xxxxx
Date: 10/03/01

**This is a representation of an electronic record that was signed
electronically and
this page is the manifestation of the electronic signature.**

/s/

Jonathan Wilkin
10/10/01 12:42:31 PM